ProQR Therapeutics (PRQR) Receivables (2022 - 2026)

ProQR Therapeutics (PRQR) has reported Receivables for 4 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables changed N/A year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (changed N/A YoY) and the FY2025 annual result came in at $8.1 million, up 55.24% from the prior year.
• Receivables fell to $5.4 million in Q1 2026 per PRQR's latest filing, from $8.1 million in the prior quarter.
• Over the last five years, Receivables for PRQR reached as high as $64.4 million in Q4 2022 and fell as low as $5.2 million in Q4 2024.
• A 4-year average of $20.8 million and a median of $6.7 million in 2026 frame the typical range for Receivables.
• The largest YoY upside for Receivables was 55.24% in 2025 against a maximum downside of 55.24% in 2025.
• Year by year, Receivables stood at $64.4 million in 2022, then slumped by 91.91% to $5.2 million in 2024, then jumped by 55.24% to $8.1 million in 2025, then sank by 33.61% to $5.4 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $5.4 million, $8.1 million, and $5.2 million for Q1 2026, Q4 2025, and Q4 2024 respectively.